Minimally Invasive Hypoglossal Nerve Stimulator Enabled by ECG Sensor and WPT to Manage Obstructive Sleep Apnea.

A hypoglossal nerve stimulator (HGNS) is an invasive device that is used to treat obstructive sleep apnea (OSA) through electrical stimulation. The conventional implantable HGNS device consists of a stimuli generator, a breathing sensor, and electrodes connected to the hypoglossal nerve via leads. However, this implant is bulky and causes significant trauma. In this paper, we propose a minimally invasive HGNS based on an electrocardiogram (ECG) sensor and wireless power transfer (WPT), consisting of a wearable breathing monitor and an implantable stimulator. The breathing external monitor utilizes an ECG sensor to identify abnormal breathing patterns associated with OSA with 88.68% accuracy, achieved through the utilization of a convolutional neural network (CNN) algorithm. With a skin thickness of 5 mm and a receiving coil diameter of 9 mm, the power conversion efficiency was measured as 31.8%. The implantable device, on the other hand, is composed of a front-end CMOS power management module (PMM), a binary-phase-shift-keying (BPSK)-based data demodulator, and a bipolar biphasic current stimuli generator. The PMM, with a silicon area of 0.06 mm2 (excluding PADs), demonstrated a power conversion efficiency of 77.5% when operating at a receiving frequency of 2 MHz. Furthermore, it offers three-voltage options (1.2 V, 1.8 V, and 3.1 V). Within the data receiver component, a low-power BPSK demodulator was ingeniously incorporated, consuming only 42 µW when supplied with a voltage of 0.7 V. The performance was achieved through the implementation of the self-biased phase-locked-loop (PLL) technique. The stimuli generator delivers biphasic constant currents, providing a 5 bit programmable range spanning from 0 to 2.4 mA. The functionality of the proposed ECG- and WPT-based HGNS was validated, representing a highly promising solution for the effective management of OSA, all while minimizing the trauma and space requirements.

Flexible Solution-Processable Black-Phosphorus-Based Optoelectronic Memristive Synapses for Neuromorphic Computing and Artificial Visual Perception Applications.

Being renowned for operating with visible-light pulses and electrical signals, optoelectronic memristive synaptic devices have excellent potential for neuromorphic computing systems and artificial visual information processing. Here, a flexible back-end-of-line-compatible optoelectronic memristor based on a solution-processable black phosphorus/HfOx bilayer with excellent synaptic features, toward biomimetic retinas is presented. The device shows highly stable synaptic features such as long-term potentiation (LTP) and long-term depression (LTD) for repetitive 1000 epochs, having 400 conductance pulses, each. The device presents advanced synaptic features in terms of long-term memory (LTM)/short term memory (STM), as well as learning-forgetting-relearning when visible light is induced on it. These advanced synaptic features can improve the information processing abilities for neuromorphic applications. Interestingly, the STM can be converted into LTM by adjusting the intensity of light and illumination time. Using the light-induced characteristics of the device, a 6 × 6 synaptic array is developed to exhibit possible use in artificial visual perception. Moreover, the devices are flexed using a silicon back-etching process. The resulting flexible devices demonstrate stable synaptic features when bent down to 1 cm radius. These multifunctional features in a single memristive cell make it highly suitable for optoelectronic memory storage, neuromorphic computing, and artificial visual perception applications.

Hyaluronic acid functionalized biodegradable mesoporous silica nanocomposites for efficient photothermal and chemotherapy in breast cancer.

Chemotherapy is one of conventional treatment methods for breast cancer, but drug toxicity and side effects have severely limited its clinical applications. Photothermal therapy has emerged as a promising method that, upon combination with chemotherapy, can better treat breast cancer. In this context, a biodegradable mesoporous silica nanoparticle (bMSN NPs) system was developed for loading doxorubicin (DOX) and IR780, to be potentially applied in the treatment of breast cancer. IR780 is encapsulated in the pores of bMSN NPs by hydrophobic adsorption, while DOX is adsorbed on the surface of the bMSN NPs by hyaluronic acid electrostatically, to form the bMID NPs. Transmission electron microscopy, fluorescence spectrum and UV absorption spectrum are used to prove the successful encapsulation of IR780 and the loading of DOX. In vitro experiments have shown bMID NPs present an excellent therapeutic effect on breast cancer cells. In vivo fluorescence imaging results have indicated that bMID NPs can accumulate in tumor sites gradually and achieve in vivo long-term circulation and continuous drug release. Furthermore, bMID NPs have provided obvious antitumor effects in breast cancer mouse models, thus evolving as an efficient platform for breast cancer therapy.